– First Preclinical Data for Pan-RAF Inhibitor
DCC-3084 to be Presented; IND Filing Expected in Second Half of
2023 –
– New Preclinical Data Supports ULK inhibitor
DCC-3116 in Combination with QINLOCK® in GIST and in Combination
with Encorafenib and Cetuximab in Colorectal Cancer; Expects to
Initiate Two New Combination Escalation Studies in Second Half of
2023 –
– New Pan-KIT Development Candidate DCC-3009
for GIST Demonstrates Potential Best-in-Class Profile with Broad
Coverage of KIT Mutations with High Selectivity –
– Company Discloses New Research Programs
Focused on Novel Integrated Stress Response Targets GCN2 and PERK
–
– Company to Host Virtual Investor Event on
Tuesday, April 18 at 6:30 PM ET –
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a
biopharmaceutical company focused on discovering, developing, and
commercializing important new medicines to improve the lives of
people with cancer, today announced the presentation of eight
posters at the upcoming AACR Annual Meeting 2023, taking place in
Orlando, Florida on April 14-19, 2023. The Company will also host a
virtual investor event on Tuesday, April 18 at 6:30 PM ET.
“We are excited to share new preclinical data that demonstrate
the breadth and depth of our research capabilities based on our
proprietary switch-control kinase inhibitor platform and its
ability to generate new opportunities for potential first- and
best-in-class kinase inhibitors,” said Steve Hoerter, President and
Chief Executive Officer of Deciphera. “At the upcoming AACR
meeting, we look forward to presenting preclinical data supporting
our next Investigational New Drug (IND) candidate, DCC-3084, a
potential best-in-class pan-RAF inhibitor that broadly inhibits
Class I, II, and III BRAF mutations, BRAF fusions, and BRAF/CRAF
heterodimers. In addition, we will present preclinical data on our
ULK inhibitor, DCC-3116, in combination with QINLOCK in
gastrointestinal stromal tumor (GIST) and in combination with
encorafenib and cetuximab in colorectal cancer that strongly
support two new dose escalation combination studies that we expect
to initiate in the second half of this year.”
Mr. Hoerter continued, “We continue to expand our leadership
position in GIST with the addition of our newest development
candidate, DCC-3009, a potential best-in-class pan-KIT inhibitor,
which preclinically has demonstrated its ability to potently and
very selectively inhibit the broad spectrum of known primary and
secondary drug-resistant mutations in GIST, spanning KIT exons 9,
11, 13, 14, 17, and 18. Finally, we are excited to share initial
preclinical data on two new programs, GCN2 and PERK, two novel
targets focused on the integrated stress response, which is a major
adaptive stress response pathway in cancer.”
Copies of the abstracts are available on AACR’s website.
Presentation details are as follows:
Poster Number: 4872 Title: DCC-3116, a
first-in-class selective inhibitor of ULK1/2 kinases and autophagy,
in combination with the KIT inhibitor ripretinib induces complete
regressions in GIST preclinical models Presenter: Madhumita
Bogdan, Ph.D., Senior Principal Investigator, Biological Sciences,
Deciphera Pharmaceuticals Session Date: Tuesday, April 18
Session Time: 1:30 – 5:00 PM ET
Poster Number: 1377 Title: DCC-3116, a
first-in-class selective inhibitor of ULK1/2 kinases and autophagy,
synergizes with encorafenib and cetuximab in BRAF V600E mutant
colorectal cancer models Presenter: Madhumita Bogdan, Ph.D.,
Senior Principal Investigator, Biological Sciences, Deciphera
Pharmaceuticals Session Date: Monday, April 17 Session
Time: 9:00 AM – 12:30 PM ET
Poster Number: 4033 Title: Pan-exon mutant KIT
inhibitor DCC-3009 demonstrates tumor regressions in preclinical
gastrointestinal stromal tumor models Presenter: Bryan
Smith, Ph.D., Vice President, Biological Sciences, Deciphera
Pharmaceuticals Session Date: Tuesday, April 18 Session
Time: 9:00 AM – 12:30 PM ET
Poster Number: 4045 Title: DCC-3084, a RAF dimer
inhibitor, broadly inhibits BRAF class I, II, III, BRAF fusions,
and RAS-driven solid tumors leading to tumor regression in
preclinical models Presenter: Stacie Bulfer, Ph.D., Senior
Director, Biological Sciences, Deciphera Pharmaceuticals Session
Date: Tuesday, April 18 Session Time: 9:00 AM – 12:30 PM
ET
Poster Number: 4938 Title: DP-9024, an
investigational small molecule modulator of the Integrated Stress
Response kinase GCN2, synergizes with asparaginase therapy in
leukemic tumors Presenter: Qi Groer, M.S., Scientist,
Biological Sciences, Deciphera Pharmaceuticals Session Date:
Tuesday, April 18 Session Time: 1:30 – 5:00 PM ET
Poster Number: 1639 Title: DP-9149, an
investigational small molecule modulator of the Integrated Stress
Response kinase GCN2, pre-clinically causes solid tumor growth
inhibition as a single agent and regression in combination with
standard of care agents Presenter: Gada Al-Ani, Ph.D.,
Senior Principal Investigator, Biological Sciences, Deciphera
Pharmaceuticals Session Date: Monday, April 17 Session
Time: 9:00 AM – 12:30 PM ET
Poster Number: 1640 Title: DP-9024, an
investigational small molecule modulator of the Integrated Stress
Response kinase PERK, causes B-cell cancer growth inhibition as
single agent and in combination with standard-of-care agents
Presenter: Gada Al-Ani, Ph.D., Senior Principal
Investigator, Deciphera Pharmaceuticals Session Date:
Monday, April 17 Session Time: 9:00 AM – 12:30 PM ET
Poster Number: 1613 Title: Dimerization-induced
activation of the Integrated Stress Response kinase PERK by an
investigational small molecule modulator, DP-9024 Presenter:
Aaron Rudeen, Ph.D., Senior Scientist, Deciphera Pharmaceuticals
Session Date: Monday, April 17 Session Time: 9:00 AM
– 12:30 PM ET
Conference Call and Webcast
Deciphera will host a virtual investor event on Tuesday, April
18 at 6:30 PM ET. The event may be accessed by registering at
https://deciphera-2023-aacr-investor-event.open-exchange.net/. A
webcast of the event will be available in the “Events and
Presentations” page in the “Investors” section of the Company’s
website at https://investors.deciphera.com/events-presentations.
The archived webcast will be available on the Company’s website
within 24 hours after the event and will be available for 30 days
following the event.
About Deciphera Pharmaceuticals
Deciphera is a biopharmaceutical company focused on discovering,
developing, and commercializing important new medicines to improve
the lives of people with cancer. We are leveraging our proprietary
switch-control kinase inhibitor platform and deep expertise in
kinase biology to develop a broad portfolio of innovative
medicines. In addition to advancing multiple product candidates
from our platform in clinical studies, QINLOCK® is Deciphera’s
switch-control inhibitor for the treatment of fourth-line GIST.
QINLOCK is approved in Australia, Canada, China, the European
Union, Hong Kong, Israel, Macau, New Zealand, Switzerland, Taiwan,
the United Kingdom, and the United States. For more information,
visit www.deciphera.com and follow us on LinkedIn and Twitter
(@Deciphera).
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, our expectations
and timing regarding the potential for our preclinical and/or
clinical stage pipeline assets to be first-in-class and/or
best-in-class treatments; plans to file an IND for DCC-3084 in the
second half of 2023; plans to initiate two new combination
escalation studies with DCC-3116 in the second half of 2023 in GIST
and CRC; the potential for DCC-3009 to be a broad-spectrum KIT
inhibitor in GIST. The words “may,” “will,” “could,” “would,”
“should,” “expect,” “plan,” “anticipate,” “intend,” “believe,”
“estimate,” “predict,” “project,” “potential,” “continue,” “seek,”
“target” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Any forward-looking
statements in this press release are based on management’s current
expectations and beliefs and are subject to a number of risks,
uncertainties and important factors that may cause actual events or
results to differ materially from those expressed or implied by any
forward-looking statements contained in this press release,
including, without limitation, our ability to successfully
demonstrate the efficacy and safety of our drug or drug candidates
and in additional indications for our existing drug, the
preclinical or clinical results for our drug candidates, which may
not support further development of such drug candidates, comments,
feedback and actions of regulatory agencies, our ability to
commercialize QINLOCK and execute on our marketing plans for any
drugs or indications that may be approved in the future, the
inherent uncertainty in estimates of patient populations,
competition from other products, our ability to obtain and maintain
reimbursement for any approved product and the extent to which
patient assistance programs are utilized and other risks identified
in our Securities and Exchange Commission (SEC) filings, including
our Annual Report on Form 10-K for the year ended December 31,
2022, and subsequent filings with the SEC. We caution you not to
place undue reliance on any forward-looking statements, which speak
only as of the date they are made. We disclaim any obligation to
publicly update or revise any such statements to reflect any change
in expectations or in events, conditions or circumstances on which
any such statements may be based, or that may affect the likelihood
that actual results will differ from those set forth in the
forward-looking statements.
Deciphera, the Deciphera logo, QINLOCK, and the QINLOCK logo are
registered trademarks of Deciphera Pharmaceuticals, LLC.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230314005850/en/
Investor Relations: Maghan Meyers Argot Partners
Deciphera@argotpartners.com 212-600-1902
Media: David Rosen Argot Partners
david.rosen@argotpartners.com 212-600-1902
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From May 2024 to Jun 2024
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Jun 2023 to Jun 2024